CTRI/2022/10/046779尚未招募未知
A Double-Blind, Randomized, Placebo Controlled, Parallel Group,Clinical Trial Assessing the Effectiveness and Safety of VISPO on Urinary Symptoms in Female Subjects.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Women with frequent urination, nocturia, and/or urgency for at least 2 months
- •2.Urinary symptoms that do not require medical treatment based on definitions by physicians
- •3.Must be able to read and understand in English or local language and maintain a subject diary
- •4.Must be willing and able to give informed consent and comply with the study procedures.
排除标准
- •1.Suspected to have overactive bladder (OAB) according to the core lower urinary tract symptom score (CLSS) and the OAB symptom score (OABSS).
- •2.Currently receiving or have received treatments for urinary disorders within the past 2 months
- •3.Subjects who are unable to have the desire to urinate.
- •4.Subjects who have dysuria as the main symptom
- •5.Subjects allergic to herbal products or any component of the study product
- •6.History of uncontrolled chronic or lifestyle related disease
- •7. Known HIV or Hepatitis B positive or any other immuno-compromised state
- •8. Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study
- •9. Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study.
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.Estudio fase II de distribución aleatoria, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia de la administración oral durante 28 días de AZD1236 a pacientes adultos con fibrosis quística - CYBERCystic FibrosisFibrosis quísticaMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2008-004699-34-ESAstraZeneca AB50
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen, Oral Non-Conjugated Equine Estrogen, or No Estrogen Therapy - ADOREHypoactive sexual desire disorderEUCTR2006-001179-39-DEProcter & Gamble Pharmaceuticals270
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2006-001009-27-HUBoehringer Ingelheim Pharma GesmbH3,000
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).EUCTR2010-019695-76-EEGlaxoSmithKline Research & Development675
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-SEGlaxoSmithKline AB736